Ivan M Robbins
Overview
Explore the profile of Ivan M Robbins including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
85
Citations
4729
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Robbins I, Hemnes A
Pulm Circ
. 2025 Feb;
15(1):e70059.
PMID: 40013009
Epoprostenol is a prostaglandin that was first identified by investigators in 1976 and found to be a potent vasodilator and inhibiter of platelet aggregation, initially in animal studies and subsequently...
2.
Trindade A, Chapin K, Gray J, Furuya Y, Mullican A, Hoy H, et al.
Transplant Direct
. 2023 May;
9(6):e1487.
PMID: 37250487
Methods: We prospectively measured plasma dd-cfDNA% every 3 to 4 mo in patients ≥2 y post-lung transplant. ALAD was defined as infection, acute cellular rejection, possible antibody-mediated rejection, or change...
3.
Trindade A, Chapin K, Mullican A, Gray J, Hoy H, Demarest C, et al.
Transplant Direct
. 2022 Nov;
8(12):e1411.
PMID: 36406896
Methods: We performed a prospective, single-center, observational study to identify plasma dd-cfDNA levels in clinically stable lung allograft recipients >2 y posttransplant. Results: Fifty-one subjects were enrolled and ≥3 baseline...
4.
Trindade A, Chapin K, Gannon W, Hoy H, Demarest C, Lambright E, et al.
Transpl Infect Dis
. 2022 Oct;
24(6):e13967.
PMID: 36271645
Background: Reports on outcomes following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in lung transplant recipients remain limited. Methods: We performed a single-center, observational study of outcomes in lung...
5.
Trindade A, Gannon W, Stokes J, Lambright E, McPherson K, Norfolk S, et al.
Transplant Direct
. 2022 Oct;
8(10):e1371.
PMID: 36204187
No abstract available.
6.
de Perrot M, Gopalan D, Jenkins D, Lang I, Fadel E, Delcroix M, et al.
J Heart Lung Transplant
. 2021 Aug;
40(11):1301-1326.
PMID: 34420851
ISHLT members have recognized the importance of a consensus statement on the evaluation and management of patients with chronic thromboembolic pulmonary hypertension. The creation of this document required multiple steps,...
7.
Kerr K, Elliott C, Chin K, Benza R, Channick R, Davis R, et al.
Chest
. 2021 Jun;
160(5):1822-1831.
PMID: 34090871
Background: The United States Chronic Thromboembolic Pulmonary Hypertension Registry (US-CTEPH-R) was designed to characterize the demographic characteristics, evaluation, clinical course, and outcomes of surgical and nonsurgical therapies for patients with...
8.
Brittain E, Niswender K, Agrawal V, Chen X, Fan R, Pugh M, et al.
J Am Heart Assoc
. 2020 Nov;
9(22):e018349.
PMID: 33167773
Background Metabolic dysfunction is highly prevalent in pulmonary arterial hypertension (PAH) and likely contributes to both pulmonary vascular disease and right ventricular (RV) failure in part because of increased oxidant...
9.
Huston J, Brittain E, Robbins I
Cardiol Clin
. 2020 Apr;
38(2):269-281.
PMID: 32284103
Pulmonary arterial hypertension is a highly morbid disease with limited treatment options that improve survival and currently the only curative treatment is transplantation. There is a small body of literature...
10.
Agrawal V, DAlto M, Naeije R, Romeo E, Xu M, Assad T, et al.
J Am Heart Assoc
. 2019 Sep;
8(17):e012504.
PMID: 31475602
Background Identification of occult diastolic dysfunction often requires invasive right heart catheterization with provocative maneuvers such as fluid challenge. Non-invasive predictors of occult diastolic dysfunction have not been identified. We...